Publications
] "Addressing cell-sourcing limitations with gene therapy." IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society 22, no. 5 (2003): 65-70.
"Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Experimental cell research 300, no. 2 (2004): 406-417.
"Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.
"Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnology and bioengineering 88, no. 3 (2004): 369-378.
"Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions - 7th World Biomaterials Congress (2004).
"Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries." Biomaterials 26, no. 22 (2005): 4523-4531.
"Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (2005): 603-604.
"Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials." Annals of oncology : official journal of the European Society for Medical Oncology 16, no. 4 (2005): 558-565.
"Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation." Journal of cell science 119, no. Pt 3 (2006): 581-591.
"Inducible regulation of Runx2-stimulated osteogenesis." Gene therapy 13, no. 11 (2006): 873-882.
"Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
"Genetic engineering for skeletal regenerative medicine." Annual review of biomedical engineering 9 (2007): 87-119.
"Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2." Journal of cellular biochemistry 102, no. 6 (2007): 1458-1471.
"In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts." Journal of cellular biochemistry 100, no. 5 (2007): 1324-1336.
"Virus-based gene therapy strategies for bone regeneration." Biomaterials 28, no. 2 (2007): 211-229.
"Synthesis of programmable integrases." Proceedings of the National Academy of Sciences of the United States of America 106, no. 13 (2009): 5053-5058.
"Directed evolution of recombinase specificity by split gene reassembly." Nucleic acids research 38, no. 12 (2010): 4198-4206.
"Engineered bioactive molecules." 5 (2011): 131-145.
"Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of the United States of America 108, no. 2 (2011): 510-515.
"Structure-guided reprogramming of serine recombinase DNA sequence specificity." Proceedings of the National Academy of Sciences of the United States of America 108, no. 2 (2011): 498-503.
"Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase." Nucleic acids research 39, no. 17 (2011): 7868-7878.
"Advances in targeted genome editing." Current opinion in chemical biology 16, no. 3-4 (2012): 268-277.
"Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases." Nucleic Acids Research 40, no. 8 (2012): 3741-3752.
"Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases." Nucleic Acids Research 40, no. 8 (2012): 3741-3752.
"Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors." Journal of the American Chemical Society 134, no. 40 (2012): 16480-16483.